Literature DB >> 29800370

Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.

Jesica A Swanstrom1, Sandra Henein2, Jessica A Plante1, Boyd L Yount1, Douglas G Widman1, Emily N Gallichotte2, Hansi J Dean3, Jorge E Osorio3, Charalambos D Partidos3, Aravinda M de Silva2, Ralph S Baric1,2.   

Abstract

Background: Dengue virus serotypes 1-4 (DENV-1-4) are the most common vector-borne viral pathogens of humans and the etiological agents of dengue fever and dengue hemorrhagic syndrome. A live-attenuated tetravalent dengue vaccine (TDV) developed by Takeda Vaccines has recently progressed to phase 3 safety and efficacy evaluation.
Methods: We analyzed the qualitative features of the neutralizing antibody (nAb) response induced in naive and DENV-immune individuals after TDV administration. Using DENV-specific human monoclonal antibodies (mAbs) and recombinant DENV displaying different serotype-specific Ab epitopes, we mapped the specificity of TDV-induced nAbs against DENV-1-3.
Results: Nearly all subjects had high levels of DENV-2-specific nAbs directed to epitopes centered on domain III of the envelope protein. In some individuals, the vaccine induced nAbs that tracked with a DENV-1-specific neutralizing epitope centered on domain I of the envelope protein. The vaccine induced binding Abs directed to a DENV-3 type-specific neutralizing epitope, but findings of mapping of DENV-3 type-specific nAbs were inconclusive.
Conclusion: Here we provide qualitative measures of the magnitude and epitope specificity of the nAb responses to TDV. This information will be useful for understanding the performance of TDV in clinical trials and for identifying correlates of protective immunity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29800370      PMCID: PMC5972589          DOI: 10.1093/infdis/jiy063

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

Authors:  Claire Y-H Huang; Siritorn Butrapet; Kiyotaka R Tsuchiya; Natth Bhamarapravati; Duane J Gubler; Richard M Kinney
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  A prospective study of dengue infections in Bangkok.

Authors:  D S Burke; A Nisalak; D E Johnson; R M Scott
Journal:  Am J Trop Med Hyg       Date:  1988-01       Impact factor: 2.345

3.  Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.

Authors:  Xavier Sáez-Llorens; Vianney Tricou; Delia Yu; Luis Rivera; Suely Tuboi; Pedro Garbes; Astrid Borkowski; Derek Wallace
Journal:  Lancet Infect Dis       Date:  2017-03-30       Impact factor: 25.071

4.  Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Authors:  Usha K Nivarthi; Nurgun Kose; Gopal Sapparapu; Douglas Widman; Emily Gallichotte; Jennifer M Pfaff; Benjamin J Doranz; Daniela Weiskopf; Alessandro Sette; Anna P Durbin; Steve S Whitehead; Ralph Baric; James E Crowe; Aravinda M de Silva
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

5.  Dengue viruses cluster antigenically but not as discrete serotypes.

Authors:  Leah C Katzelnick; Judith M Fonville; Gregory D Gromowski; Jose Bustos Arriaga; Angela Green; Sarah L James; Louis Lau; Magelda Montoya; Chunling Wang; Laura A VanBlargan; Colin A Russell; Hlaing Myat Thu; Theodore C Pierson; Philippe Buchy; John G Aaskov; Jorge L Muñoz-Jordán; Nikos Vasilakis; Robert V Gibbons; Robert B Tesh; Albert D M E Osterhaus; Ron A M Fouchier; Anna Durbin; Cameron P Simmons; Edward C Holmes; Eva Harris; Stephen S Whitehead; Derek J Smith
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

6.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.

Authors:  Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville
Journal:  N Engl J Med       Date:  2015-07-27       Impact factor: 91.245

7.  Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.

Authors:  Sandra Henein; Jesica Swanstrom; Anthony M Byers; Janice M Moser; S Farzana Shaik; Matthew Bonaparte; Nicholas Jackson; Bruno Guy; Ralph Baric; Aravinda M de Silva
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

8.  DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers.

Authors:  Guntur Fibriansah; Kristie D Ibarra; Thiam-Seng Ng; Scott A Smith; Joanne L Tan; Xin-Ni Lim; Justin S G Ooi; Victor A Kostyuchenko; Jiaqi Wang; Aravinda M de Silva; Eva Harris; James E Crowe; Shee-Mei Lok
Journal:  Science       Date:  2015-07-03       Impact factor: 47.728

9.  A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins.

Authors:  Guntur Fibriansah; Joanne L Tan; Scott A Smith; Ruklanthi de Alwis; Thiam-Seng Ng; Victor A Kostyuchenko; Ramesh S Jadi; Petra Kukkaro; Aravinda M de Silva; James E Crowe; Shee-Mei Lok
Journal:  Nat Commun       Date:  2015-02-20       Impact factor: 14.919

10.  A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface.

Authors:  Guntur Fibriansah; Joanne L Tan; Scott A Smith; Adamberage R de Alwis; Thiam-Seng Ng; Victor A Kostyuchenko; Kristie D Ibarra; Jiaqi Wang; Eva Harris; Aravinda de Silva; James E Crowe; Shee-Mei Lok
Journal:  EMBO Mol Med       Date:  2014-01-13       Impact factor: 12.137

View more
  7 in total

1.  Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.

Authors:  Ellen Young; Robert H Carnahan; Daniela V Andrade; Nurgun Kose; Rachel S Nargi; Ethan J Fritch; Jennifer E Munt; Michael P Doyle; Laura White; Thomas J Baric; Mark Stoops; Aravinda DeSilva; Longping V Tse; David R Martinez; Deanna Zhu; Stefan Metz; Marcus P Wong; Diego A Espinosa; Magelda Montoya; Scott B Biering; Soila Sukulpolvi-Petty; Guillermina Kuan; Angel Balmaseda; Michael S Diamond; Eva Harris; James E Crowe; Ralph S Baric
Journal:  Cell Host Microbe       Date:  2020-05-13       Impact factor: 21.023

2.  Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a Live-Attenuated Tetravalent Dengue Vaccine Candidate.

Authors:  Mayuri Sharma; Dustin R Glasner; Heather Watkins; Henry Puerta-Guardo; Yoseph Kassa; Michael A Egan; Hansi Dean; Eva Harris
Journal:  J Infect Dis       Date:  2020-03-02       Impact factor: 5.226

3.  Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).

Authors:  Laura J White; Ellen F Young; Mark J Stoops; Sandra R Henein; Elizabeth C Adams; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Negl Trop Dis       Date:  2021-03-12

4.  Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas.

Authors:  Daniela V Andrade; Colin Warnes; Ellen Young; Leah C Katzelnick; Angel Balmaseda; Aravinda M de Silva; Ralph S Baric; Eva Harris
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

Review 5.  Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?

Authors:  Jedhan Ucat Galula; Gielenny M Salem; Gwong-Jen J Chang; Day-Yu Chao
Journal:  Hum Vaccin Immunother       Date:  2019-08-23       Impact factor: 3.452

6.  Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003.

Authors:  Huy A Tu; Usha K Nivarthi; Nancy R Graham; Philip Eisenhauer; Matthew J Delacruz; Kristen K Pierce; Stephen S Whitehead; Jonathan E Boyson; Jason W Botten; Beth D Kirkpatrick; Anna P Durbin; Aravinda M deSilva; Sean A Diehl
Journal:  Cell Rep Med       Date:  2020-12-22

Review 7.  Anti-dengue Vaccines: From Development to Clinical Trials.

Authors:  Josilene Ramos Pinheiro-Michelsen; Rayane da Silva Oliveira Souza; Itana Vivian Rocha Santana; Patrícia de Souza da Silva; Erick Carvalho Mendez; Wilson Barros Luiz; Jaime Henrique Amorim
Journal:  Front Immunol       Date:  2020-06-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.